816 NT-I7 and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that favors anti-tumor efficacy in combination with checkpoint inhibitors

• Miyoung Kim,
• Donghoon Choi,
• Sara Ferrando-Martinez,
• Eunju Lee,
• Minji Lee,
• Sun-Kyoung Im,
• Seungtae Baek,
• Mankyu Ji,
• Seung Taek Ji,
• Daeun Kim,
• Jun-Young Lee

Affiliations

Miyoung Kim

1NeoImmuneTech, Co., Ltd., Pohang-si, Republic of Korea

Donghoon Choi

1NeoImmuneTech, Co., Ltd., Pohang-si, Republic of Korea

Sara Ferrando-Martinez

5NeoImmuneTech, Inc., Rockville, MD, USA

Eunju Lee

1NeoImmuneTech, Co., Ltd., Pohang-si, Republic of Korea

Minji Lee

1NeoImmuneTech, Co., Ltd., Pohang-si, Republic of Korea

Sun-Kyoung Im

1NeoImmuneTech, Co., Ltd., Pohang-si, Republic of Korea

Seungtae Baek

1NeoImmuneTech, Co., Ltd., Pohang-si, Republic of Korea

Mankyu Ji

1NeoImmuneTech, Co., Ltd., Pohang-si, Republic of Korea

Seung Taek Ji

1NeoImmuneTech, Co., Ltd., Pohang-si, Republic of Korea

Daeun Kim

3Selecxine Inc., Co., Ltd., Seoul, Republic of Korea

Jun-Young Lee

3Selecxine Inc., Co., Ltd., Seoul, Republic of Korea